Q32 Bio Prices $200M Offering at $18.25, a 63% Premium to Pre-Data Price
QTTB has more than doubled off its 52-week low of $1.569 on elevated volume (5.1× avg).
Summary
Q32 Bio priced its follow-on offering at $18.25 per share, a 63% premium to the pre-data price, raising ~$188M net (up to ~$216M with the greenshoe). This follows the July 13 announcement of positive Phase 2a bempikibart data and the initial $200M offering plan. The strong pricing reflects robust demand after the clinical readout. Underwriters include Morgan Stanley, Jefferies, Cantor Fitzgerald, and Oppenheimer. Proceeds will fund bempikibart development and general corporate purposes.
At the time of this announcement, QTTB was trading at $16.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $371.8M. The 52-week trading range was $1.57 to $23.57. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.